Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Fig. 1

Survivin expression in RCC tumor tissues versus in the associated normal tissues: Boxplots of the BIRC5 (survivin) expression level across TCGA-RCC subtypes in renal tumor (red) versus the associated normal renal tissues (blue) were presented (A). BIRC5/survivin expression among different stages of chRCC (B), ccRCC (C) and pRCC (D) versus associated normal tissues was box-plotted. BIRC5/survivin expression was presented in the log2 (TPM + 1) scale format. Data were presented as the mean ± standard deviation (SD). A t-test was used to evaluate the statistical significance of the mRNA expression level in normal renal versus tumor tissues. One-way ANOVA was used to compare BIRC5/survivin expression among normal renal tissues versus different stages of RCC tumor tissues. The figure was performed using R version 4.0.3

Back to article page